PeptideIntel

CagriSema (Cagrilintide + Semaglutide)

The investigational amylin-plus-GLP-1 combination — not a grey-market stack but a single fixed-dose drug candidate in late-stage trials, pairing two distinct appetite-suppression mechanisms.

Last updated

Components

Cagrilintide

RCT

AM833 · cagri

An investigational long-acting amylin analog — interesting on its own in phase 2, but its real momentum is as the partner to semaglutide in the CagriSema combination.

In clinical trials

Semaglutide

RCT

Ozempic · Wegovy

The GLP-1 agonist that defined the modern weight-loss era — FDA-approved, backed by the large STEP and SUSTAIN trials, and now with cardiovascular-outcome data behind it.

FDA-approved

Rationale (from the literature)

Unlike the research-peptide stacks elsewhere on this site, CagriSema is a deliberate pharmaceutical combination being developed as one product, not a protocol assembled by users. The logic is mechanistic and well-grounded: semaglutide is a GLP-1 agonist, while cagrilintide is a long-acting amylin analog — two different appetite-regulating pathways. Engaging both at once is expected to suppress appetite more than either alone, and a phase 2 trial in type 2 diabetes (Frías et al., 2023, Lancet) showed the combination produced larger weight and glycemic reductions than its individual components. The phase 3 program is what will establish whether the combination is meaningfully better than the (already very effective) GLP-1 agonists on their own.

Honest caveats

  • Investigational — CagriSema is not approved by any regulator and is available only in clinical trials
  • Semaglutide is a prescription drug and cagrilintide is an investigational drug; neither belongs in a self-assembled grey-market stack
  • Semaglutide carries a boxed warning for thyroid C-cell tumors and risks of pancreatitis and gallbladder disease — the combination does not remove these
  • GI effects (nausea, vomiting) are expected and can be additive across two appetite-suppressing agents
  • Reported phase 3 results have at times undershot expectations — combination superiority over semaglutide alone is not yet settled
  • This is a medical product under investigation, not a protocol to replicate; access is via trials and, eventually, a licensed prescriber only